Menu
Back to Journals » Biologics: Targets and Therapy » Volume 2 » Issue 1
Bevacizumab in the therapy for refractory metastatic colorectal cancer
Authors Mulcahy MF
Published 7 March 2008 Volume 2008:2(1) Pages 53—59
Mary F Mulcahy
Northwestern University, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago IL, USA
Abstract: Colorectal cancer is the second most common cause of cancer related deaths in the United States. Recent developments have led to prolonged survival with the use of sequential lines of chemotherapy agents. The addition of bevacizumab to active chemotherapy has further improved survival when used in the first and second lines of therapy for metastatic colorectal cancer. Evidence supporting the continued use of bevacizumab throughout lines of therapy is accumulating. Clinical trials are underway in which bevacizumab is continued beyond the first line of a chemotherapy and bevacizumab combination regimen. The mechanism by which colorectal cancer may become resistant to bevacizumab is poorly understood. Molecular and biochemical correlates which may identify bevacizumab resistance are an important component in the design of these clinical trials.
Keywords: colorectal cancer, bevacizumab, refractory
© 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.